Atrial Fibrillation Flashcards

1
Q

Components of CHA2DS2VASc Score

A

C: Congestive HF
H: HTN
A: Age > 75 years (2 pts)
D: Diabetes
S: Stroke/TIA/Systemic Embolism (2 pts)
V: Vascular Disease
A: 65-74 years
Sc: Female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anticoagulation indicated in men with a CHA2DS2VASc Score ≥ ___

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Anticoagulation indicated in women with a CHA2DS2VASc Score ≥ ___

A

3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HASBLED Componenets

A

H: HTN - SBP > 160 mm Hg
A: Abnormal liver/kidney function (1 each)
S: Stroke history
B: Bleeding history
L: Labile INR
E: Elderly > 65 years
D: Drug/Alcohol abuse (1 each)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lenient Rate Control HR Goal

A

110 bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Patients who qualify for Lenient Rate Control

A

Asymptomatic AND EF > 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Strict Rate Control HR Goal

A

< 80 bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Patients who qualify for Strict Rate Control

A

Symptomatic OR EF ≤ 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Type of Cardioversion in Hemodynamically Unstable Patient

A

Immediate DCCV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Type of Cardioversion in Symptomatic Patient Desite Rate Control

A

DCCV, Chemical Cardioversion, or Both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Type of Cardioversion in a Patient Unable to Achieve Rate Control

A

DCCV, Chemical Cardioversion, or Both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Type of Cardioversion in a Patient Unable to Achieve Rate Control

A

DCCV, Chemical Cardioversion, or Both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Vaughan-Williams Class I Anti-arrhythmic Class

A

Sodium Channel Blockade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Vaughan-Williams Class I Anti-arrhythmics

A

Ia: Disopyramide, quinidine, procainamide
1b: Lidoacine, mexiletine
1c: Flecainide, Propafenone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Vaughan-Williams Class II Anti-arrhythmics Class

A

Beta-blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Vaughan-Williams Class III Anti-arrhythmics Class

A

Potassium Channel Blockade

17
Q

Vaughan-Williams Class III Anti-arrhythmics

A

Sotalol, dofetilide, amiodarone, dronedarone, ibutilide

18
Q

Vaughan-Williams Class IV Anti-arrhythmic Class

A

CCB

19
Q

Antiarrhythmics that can be used for ACUTE chemical cardioversion

A

Flecainide, propafenone, dofetilide, amiodarone, ibutilide

20
Q

Antiarrhythmics that can be used for CHRONIC Rhythm Control

A

Flecainide, propafenone, sotalol, dofetilide, amiodarone, dronedarone

21
Q

Class IC Antiarrythmics Metabolism/DDI

A

CYP2D6

22
Q

Propafenone specific AE

A

Metallic Taste

23
Q

Dofetilide Initation

A

3 days inpatient

24
Q

Dofetilide DDI

A

Verapamil: decreases absorption
HCTZ: Impacts clearance/electrolytes
Metformin/Trimethoprim: Competes for active tubular secretion
Additive QT prolongation

25
Q

Dofetide CI Renal Funciton

A

< 20 mL/min

26
Q

Sotalol Initiaton

A

3-days inpatient

27
Q

Sotalol DDI

A

Additive QT prolongation

28
Q

Sotalol CI Renal Function

A

< 40 mL/min

29
Q

Amiodarone Half-Life

A

~50 days

30
Q

Amiodarone DDI

A

Inhibits: CYP3A4, 2D6, 2C9, PGP
Additive QT prolongation

31
Q

Amiodarone load goal

A

8-10 grams over 2-4 weeks

32
Q

Amiodarone AEs

A
  1. Bradycardia
  2. QT prolongation
  3. Pulmonary fibrosis
  4. Thyroid dysfunction (hypo or hyper)
  5. Corneal deposits
  6. Hepatotoxicity
  7. Blue/Gray Skin
33
Q

Amiodarone Monitoring

A
  1. Baseline ECG, Q3-6 months
  2. Baseline TFTs, Q6 months
  3. Baseline LFTs, Q6 months
  4. Baseline CXR, Q12 months
  5. Baseline PFTs, Q12 months
34
Q

Dronedarone Brand

A

Multaq

35
Q

Dronedarone CI

A

HF, permanent AF

36
Q

Dronedarone metabolism/DDI

A

Inhibits: CYP3A4, 2D6, PGP
Additive QT prolongation

37
Q

Dronedarone AE

A
  1. Bradycardia
  2. QT prolongation
  3. Hepatotoxicity